Chronic C-type natriuretic peptide treatment attenuated hypertension and ventricular hypertrophy in spontaneously hypertensive rats by reducing inflammation and fibrosis.
Does chronic administration of C-type natriuretic peptide attenuate inflammatory and fibrotic cardiac mechanisms in normotensive and spontaneously hypertensive rats?
Chronic administration of C-type natriuretic peptide attenuates hypertension and associated cardiac remodeling by reducing inflammation and fibrosis in a rat model of spontaneous hypertension.
OBJECTIVE: Inflammation and fibrosis are key mechanisms in cardiovascular remodeling. C-type natriuretic peptide (CNP) is an endothelium-derived factor with a cardiovascular protective role, although its in-vivo effect on cardiac remodeling linked to hypertension has not been investigated. The aim of this study was to determine the effects of chronic administration of CNP on inflammatory and fibrotic cardiac mechanisms in normotensive Wistar rats and spontaneously hypertensive rats (SHR). METHODS: Twelve-week-old male SHR and normotensive rats were infused with CNP (0.75 μg/h/100 g) or isotonic saline (NaCl 0.9%) for 14 days (subcutaneous micro-osmotic pumps). Echocardiograms and electrocardiograms were performed, and SBP was measured. After treatment, transforming growth factor-beta 1, Smad proteins, tumor necrosis factor-alpha, interleukin-1 and interleukin-6, nitric oxide (NO) system and 2-thiobarbituric acid-reactive substances were evaluated in left ventricle. Histological studies were also performed. RESULTS: SHR showed lower cardiac output with signs of fibrosis and hypertrophy in left ventricle, higher NO-system activity and more oxidative damage, as well as higher pro-inflammatory and pro-fibrotic markers than normotensive rats. Chronic CNP treatment-attenuated hypertension and ventricular hypertrophy in SHR, with no changes in normotensive rats. In left ventricle, CNP induced an anti-inflammatory and antifibrotic response, decreasing both pro-fibrotic and pro-inflammatory cytokines in SHR. In addition, CNP reduced oxidative damage as well as collagen content, and upregulated the NO system in both groups. CONCLUSION: Chronic CNP treatment appears to attenuate hypertension and associated end-organ damage in the heart by reducing inflammation and fibrosis.
Caniffi et al. (Tue,) conducted a other in Hypertension. C-type natriuretic peptide (CNP) vs. Isotonic saline (NaCl 0.9%) was evaluated on Inflammatory and fibrotic cardiac mechanisms. Chronic C-type natriuretic peptide treatment attenuated hypertension and ventricular hypertrophy in spontaneously hypertensive rats by reducing inflammation and fibrosis.